• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002626.SZ
Share

Xiamen Kingdomway Group Company Stocks

CN¥ 14.09Last Updated 13.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.23B

CN¥ 14.09
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Xiamen Kingdomway Group Company operates as a global producer and distributor of a variety of nutritional and health-focused goods. The company's offerings encompass a selection of fundamental raw ingredients, notably coenzyme Q10, Vitamin A, Vitamin D3, DHA derived from microalgae, and plant-based ARA. Furthermore, it manufactures ready-to-use dietary supplements and specialized sports nutrition products. Originally established in 1997, the firm was previously recognized as Xiamen Jindawei Vitamin Co., Ltd., and maintains its principal offices in Xiamen, China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 002626.SZ is 22.0 and suggests 60.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 19:20

Volkswagen has announced plans to lay off another 50,000 employees to cut costs

13.07.2026 18:52

Kazakhstani banks topped The Banker's rankings for profitability and capital growth in Asia

13.07.2026 18:41

Chipmakers' sell-off and a new escalation in Iran: How the market opened

13.07.2026 18:05

June was TSMC's best month ever in terms of revenue. Is the AI rally continuing?

13.07.2026 17:31

"You Pay Twice for AI": Microsoft CEO Warns of Dependence on Anthropic and OpenAI

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026